Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Icagen, Inc.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.
China’s Bio-Thera Solutions is continuing to pen deals offloading commercialization rights outside of its domestic market to for its BAT2206 biosimilar Stelara (ustekinumab) candidate, this time with Biomm in Brazil.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.